Trial Profile

A Phase 1 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-4700 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MK 4700 (Primary) ; Pembrolizumab (Primary)
Indications Carcinoma; Cervical cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Skin cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
Focus Adverse reactions
Sponsors Merck Sharp & Dohme

16 Mar 2026 Actual primary completion date changed from 24 Nov 2025 to 8 Dec 2025.
11 Dec 2025 Actual primary completion date is 24 Nov 2025.
11 Dec 2025 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com